Clinical trials: Second-Line
Metastatic Colorectal Cancer
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination with irinotecan and cetuximab in K-ras…
- Trial name
- POSEIDON (NCT01008475)
- Testing
- EMD 525797 250 mg, EMD 525797 500 mg, EMD 525797 750 mg
- Where
- 62 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 232 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second or later…
- Trial name
- REGAL (NCT04229979)
- Testing
- Galinpepimut-S, Azacitidine, Venetoclax
- Where
- 73 sites in United States, France and 8 more
- Volunteers
- 127 people
- Sponsor
- Sellas Life Sciences Group
Gastrointestinal Stromal Tumors (GIST)
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
The mainstay of therapy for GISTs is surgical resection, however, recurrence is almost inevitable in high-risk tumors and secondary surgery or other salvage therapy has yielded poor outcome.
- Trial name
- NCT00633295
- Testing
- AMN107- NILOTINIB
- Where
- 3 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer, KRAS Gene Mutation
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.
- Trial name
- NCT04446793
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Sponsor
- Cardiff Oncology
Colorectal Cancer
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with…
- Trial name
- NCT00284258
- Testing
- CPT-11 and TS-1, CPT-11, 5-FU and l-LV
- Where
- Japan
- Volunteers
- 426 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Lung Cancer
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
the primary objective is to characterise the impact of gefitinib on the Response Evaluation Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ; confirmed complete response(CR) or partial response…
- Trial name
- ICARUS (NCT01530334)
- Testing
- Gefitinib 250mg
- Where
- 24 sites in Italy
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with non small cell lung cancer who have already received one platinum based chemotherapy.
- Trial name
- NCT00160043
- Testing
- SH T00268C, PTK787/ ZK 222584
- Where
- 6 sites in France, Germany
- Volunteers
- 112 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.
- Trial name
- NCT02128958
- Testing
- CF102
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 78 people
- Sponsor
- Can-Fite BioPharma
Metastatic Breast Cancer
ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (100 mg vs. 25 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer.Once…
- Trial name
- NCT00555919
- Testing
- Lonaprisan (ZK 230211, BAY86-5044)
- Where
- 28 sites in Austria, Finland and 8 more
- Volunteers
- 68 people
- Sponsor
- Bayer
Gastric Cancer, Gastroesophageal Junction Cancer
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing…
- Trial name
- NCT06346392
- Testing
- AZD0901, Ramucirumab+ paclitaxel, Paclitaxel
- Where
- 158 sites in United States, Brazil and 17 more
- Volunteers
- 594 people
- Sponsor
- AstraZeneca
Recurrent and Metastatic Gastric Cancer
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor; Apatinib is an oral selective VEGFR inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of Fluzoparib in…
- Trial name
- NCT03026881
- Testing
- Fluzoparib, Apatinib, Paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ovarian Cancer, Peritoneal Cancer
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- GLORIOSA (NCT05445778)
- Testing
- Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
- Where
- 264 sites in United States, Argentina and 20 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
- Trial name
- NCT01611558
- Testing
- Ipilimumab
- Where
- 17 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced melanoma…
- Trial name
- NCT01092585
- Testing
- Tesetaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Genta Incorporated
Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival [PFS]…
- Trial name
- NCT00447057
- Testing
- Pemetrexed, Erlotinib
- Where
- 23 sites in Austria, Germany and 3 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Advanced Pancreatic Cancer
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04239001
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Carcinoma, Hepatocellular
c-Met Second-Line Hepatocellular Carcinoma
This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A…
- Trial name
- NCT02115373
- Testing
- Tepotinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Renal Cell Carcinoma
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg…
- Trial name
- INTORSECT (NCT00474786)
- Testing
- Sorafenib, temsirolimus (Torisel)
- Where
- 128 sites in United States, Argentina and 18 more
- Volunteers
- 512 people
- Sponsor
- Pfizer
Essential Thrombocythemia
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for…
- Trial name
- SURPASS ET (NCT04285086)
- Testing
- Ropeginterferon alfa-2b, Anagrelide
- Where
- 67 sites in United States, Canada and 6 more
- Volunteers
- 174 people
- Sponsor
- PharmaEssentia